Table 1.

Clinicopathologic characteristics of HER2+ breast cancer patients according to eIF2α-P levels

Clinico-pathologic characteristic	eIF2α-P low (H-score ≤ 101.165) N = 24		eIF2α-P high (H-score > 101.165) N = 24
	Number of patients	Percentage	Number of patients	Percentage	P value
Age at diagnosis (years)
≤50	10	41.67	15	62.50	0.1486
>50	14	58.33	9	37.50
Tumor size (cm)
T0 (0–2)	10	41.67	5	20.83	0.1195
T1 (>2)	14	58.33	19	79.17
Tumor grade
Low	0	0.00	0	0.00
High	24	100.00	24	100.00
LN status
Negative	7	29.17	5	20.83	0.5050
Positive	17	70.83	19	79.17
LVI
Negative	8	33.33	6	25.00	0.5254
Positive	16	66.67	18	75.00
ER status
Negative	11	45.83	10	41.67	0.7711
Positive	13	54.17	14	58.33
PR status
Negative	14	58.33	14	58.33	1.0000
Positive	10	41.67	10	41.67
HER2 status
IHC 2+	11	45.83	3	12.50	0.0111*
IHC 3+	13	54.17	21	87.50

LN lymph node, LVI lympho-vascular invasion, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2

*p < 0.05